The follow-up, diagnosis, and rehabilitation of patients in late periods following hematopoietic stem cell transplantation: Topical issues

Hematopoietic stem cell transplantation (HSCT) is now the therapy of choice for a multitude of malignant and benign diseases in adults and children. Resultant toxic effects, sustained immunodeficiency, allo- and autoimmune responses, bone tissue malformations, and endocrine system dysfunction are an incomplete list of its complications requiring for specialists’ close observation, early diagnosis, and adequate treatment. This essay is dedicated to the follow-up, prophylactic medical examination, and rehabilitation of children after HSCT at the “Russkoe Pole” (Russian Field) Therapy and Rehabilitation Center, Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev. It shows indications for rehabilitation, the pattern and specific features of post-HSCT monitoring and recovery in children, and the relevance and importance of improving their quality of life after long-term and difficult therapy for life-threatening diseases.

1. Passweg J. R., Baldomero H., Gratwohl A. The EBMT activity survey: 1990–2010. Bone Marrow Transplant 2012;47(7):906–23.

2. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Copyright 2008© Children’s Oncology Group. www.survivorship-guidelines.org. Version 3. October 2008.

3. HCT Quick Reference Guidelines. Transplant Consultation and Posttransplant Care. Long-term survival guidelines. National Marrow Donor Program.

4. Recommended screening and preventive practices for long-term survivors after hematopoietic stem cell transplantation; Center for International Blood and Marrrow transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation (ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT). Co-published in Biol Blood Marrow Transplant 2012;18(3):337–41 and Hematol Oncol Stem Cell Ther 2012;5(1):1–30.

5. Filipovich A. H., Weisdorf D., Pavletic S. et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11(12):945–56.

6. Baird K., Cooke K., Schultz K. R. Chronic graft-versus-host disease (GVHD) in children. Paediatr Clin North Am 2010;57(1):297–322.

7. Cohen A., Békássy A. N., Gaiero A. et al.; EBMT Paediatric and Late Effects Working Parties. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplantation 2008;41 Suppl 2: S43–8.

8. Faraci M., Békássy A. N., De Fazio V. et al.; EBMT Paediatric and Late Effects Working Parties. Non-endocrine late complications in children after allogeneic haematopoietic SCT. Bone Marrow Transplantation 2008;41 Suppl 2: S49–57.

9. Styczynski J., Gil L.; EBMT Paediatric Diseases Working Party. Prevention of infectious complications in pediatric HSCT. Bone Marrow Transplantation 2008;42 Suppl 2: S77–81.

10. Patel S. R., Ortín M., Cohen B. J. et al. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis 2007;44(5):625–34.

11. Ljungman P., Cordonnier C., Einsele H. et al. Vaccination of hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2009;44(8):521–6.